BJOG : an international journal of obstetrics and gynaecology · 2025
Incidence of Acne in Women Using the Levonorgestrel-Releasing Intrauterine Device: A Systematic Review and Meta-Analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de Oliveira Elaine Cristina Fontes, de Sousa Frederico Timm Rodrigues, Lemos Felipe Augusto Oliveira, Vasconcelos Ciro Peixoto, Rocha Ana Luiza Lunardi
Аннотация
BACKGROUND: The levonorgestrel-releasing intrauterine system (LNG-IUS) is a widely used long-term contraceptive with high continuation rates, but acne may lead to discontinuation.
OBJECTIVES: To evaluate the incidence of acne among LNG-IUS users.
SEARCH STRATEGY: A systematic search was conducted in PubMed, Embase, and Cochrane Central from inception to September 2024.
SELECTION CRITERIA: Randomised clinical trials (RCTs) analysing patients of any age using LNG-IUS at 52 mg, 19.5 mg, or 13.5 mg, with acne reported as an outcome, were included.
DATA COLLECTION AND ANALYSIS: Statistical analyses were conducted using OpenMeta. Chi-square and Z-tests assessed differences between groups, and study quality was appraised using the ROB-2 tool.
MAIN RESULTS: Of 587 studies identified, nine RCTs met inclusion criteria, comprising 6305 LNG-IUS users. The overall acne incidence was 15.0% (95% CI 9.8%-20.3%). Among 2295 users of LNG-IUS 52 mg, incidence reached 19.5% (95% CI 5.2%-33.7%), whereas in 2322 users of LNG-IUS 13.5 mg it was 13.1% (95% CI 8.3%-17.9%) (p < 0.001). Two trials evaluated the 19.5 mg device but data were insufficient for pooling. Studies enrolling younger women (mean age ~24 years) reported an incidence of 19.3% (95% CI 11.0%-27.5%). Excluding Suhonen et al. yielded pooled proportions of 11.9% (95% CI 1.1%-22.7%) for LNG-IUS 52 mg users, 10.8% (95% CI 6.1%-15.5%) when all dosages were combined, and 9.9% (95% CI 9.0%-10.9%) among young women. Heterogeneity remained substantial in the overall and dosage-specific analyses (I2≈95%-97%); it was eliminated in the young women subgroup (I2 = 0%).
CONCLUSIONS: LNG-IUS 52 mg users showed a higher incidence of acne compared with those using LNG-IUS 13.5 mg. Studies enrolling younger women also showed a higher incidence. These findings suggest that device dosage and age influence acne occurrence among LNG-IUS users.
TRIAL REGISTRATION: PROSPERO registration number: CRD42024588771.
OBJECTIVES: To evaluate the incidence of acne among LNG-IUS users.
SEARCH STRATEGY: A systematic search was conducted in PubMed, Embase, and Cochrane Central from inception to September 2024.
SELECTION CRITERIA: Randomised clinical trials (RCTs) analysing patients of any age using LNG-IUS at 52 mg, 19.5 mg, or 13.5 mg, with acne reported as an outcome, were included.
DATA COLLECTION AND ANALYSIS: Statistical analyses were conducted using OpenMeta. Chi-square and Z-tests assessed differences between groups, and study quality was appraised using the ROB-2 tool.
MAIN RESULTS: Of 587 studies identified, nine RCTs met inclusion criteria, comprising 6305 LNG-IUS users. The overall acne incidence was 15.0% (95% CI 9.8%-20.3%). Among 2295 users of LNG-IUS 52 mg, incidence reached 19.5% (95% CI 5.2%-33.7%), whereas in 2322 users of LNG-IUS 13.5 mg it was 13.1% (95% CI 8.3%-17.9%) (p < 0.001). Two trials evaluated the 19.5 mg device but data were insufficient for pooling. Studies enrolling younger women (mean age ~24 years) reported an incidence of 19.3% (95% CI 11.0%-27.5%). Excluding Suhonen et al. yielded pooled proportions of 11.9% (95% CI 1.1%-22.7%) for LNG-IUS 52 mg users, 10.8% (95% CI 6.1%-15.5%) when all dosages were combined, and 9.9% (95% CI 9.0%-10.9%) among young women. Heterogeneity remained substantial in the overall and dosage-specific analyses (I2≈95%-97%); it was eliminated in the young women subgroup (I2 = 0%).
CONCLUSIONS: LNG-IUS 52 mg users showed a higher incidence of acne compared with those using LNG-IUS 13.5 mg. Studies enrolling younger women also showed a higher incidence. These findings suggest that device dosage and age influence acne occurrence among LNG-IUS users.
TRIAL REGISTRATION: PROSPERO registration number: CRD42024588771.